Arthrosamid® is an innovative hydrogel treatment that delivers proven, long-lasting relief for knee osteoarthritis — with just one injection.
Arthrosamid® is an innovative non-biodegradable hydrogel composed of 2.5% cross-linked polyacrylamide and 97.5% water. It is the first and only approved injectable implant that permanently integrates with the knee's synovial tissue.
By integrating into the tissue lining of the knee joint, it helps reduce joint stiffness, relieve pain, improve knee function, and enhance overall quality of life — all with a single treatment.
Arthrosamid® is suitable, safe and effective for most patients with knee osteoarthritis, with Health Canada approval.
Unlike hyaluronic acid injections with limited effectiveness beyond six months, Arthrosamid® offers pain reduction maintained for years.
Arthrosamid® is a simple, one-step procedure performed in one day without the usual recovery processes associated with surgery.
As Arthrosamid® integrates into the tissue lining of the knee joint, it helps soften and increase the elasticity of the tissue. This results in clinically proven reductions in joint stiffness and pain, along with improved knee function.
Arthrosamid® is a permanent injectable hydrogel that delivers long-lasting pain relief without surgery. It has redefined treatment for knee osteoarthritis.
It's this unique characteristic that provides a significant reduction in your OA pain over a longer period, with one single treatment.
Integrates with synovial tissue to soften and increase elasticity, easing joint movement.
Clinical studies demonstrate significant and sustained pain reduction after just one injection.
A minimally invasive alternative that can postpone or eliminate the need for joint replacement surgery.
Enhances knee function and overall quality of life, helping you move freely and live fully.
Arthrosamid® is backed by extensive clinical research demonstrating significant, long-lasting improvements for knee osteoarthritis patients.
A prospective, multicentre study in Denmark followed 49 participants over five years after a single injection. Results showed a statistically significant reduction in pain scores maintained throughout, with no treatment-related serious adverse events reported.
A long-term observational study assessed safety across 61 patients (89 treated knees) over 7–14 years. No significant adverse events related to the treatment were found. Of those treated, 56.2% did not require knee replacement after 10 years.
A study of 62 patients (68 knees) demonstrated a 76% overall response rate at six months. Synovial fluid analysis suggested an anti-inflammatory mechanism of action, with increased hyaluronic acid among responders.
Clinical studies show a 15% increase in synovial tissue elasticity, reducing pain signals. Arthrosamid® creates a natural barrier to inflammatory cells, and recent 2025 research shows responders have more hyaluronic acid and less IL-6 in their synovial fluid.
Mark Webb, Orthopaedic Surgeon Consultant, shares his experience.
Why leading surgeons chose to offer this treatment to their patients.
An overview of the growing number of successful treatments worldwide.
Contact us today to arrange a consultation and find out if Arthrosamid® is right for you.